SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Roberta Marongiu, Margarita Arango-Lievano, Veronica Francardo, Peter Morgenstern, Xiaoqun Zhang, M. Angela Cenci, Per Svenningsson, Paul Greengard, Michael G. Kaplitt, Gene therapy blockade of dorsal striatal p11 improves motor function and dyskinesia in parkinsonian mice, Proceedings of the National Academy of Sciences, 2016, 113, 5, 1423

    CrossRef

  2. 2
    Nadhir Litim, Marc Morissette, Thérèse Di Paolo, Metabotropic glutamate receptors as therapeutic targets in Parkinson’s disease: an update from the last 5 years of research, Neuropharmacology, 2016,

    CrossRef

  3. 3
    Mitesh Lotia, Joseph Jankovic, New and emerging medical therapies in Parkinson’s disease, Expert Opinion on Pharmacotherapy, 2016, 17, 7, 895

    CrossRef

  4. 4
    Giuseppe Gangarossa, Monica Guzman, Vania F. Prado, Marco A.M. Prado, Stephanie Daumas, Salah El Mestikawy, Emmanuel Valjent, Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia, Neurobiology of Disease, 2016, 87, 69

    CrossRef

  5. 5
    K-W Lee, L Westin, J Kim, J C Chang, Y-S Oh, B Amreen, J Gresack, M Flajolet, D Kim, A Aperia, Y Kim, P Greengard, Alteration by p11 of mGluR5 localization regulates depression-like behaviors, Molecular Psychiatry, 2015, 20, 12, 1546

    CrossRef

  6. 6
    Marie-Therese Fuzzati-Armentero, Silvia Cerri, Giovanna Levandis, Giulia Ambrosi, Elena Montepeloso, Gianfilippo Antoninetti, Fabio Blandini, Younis Baqi, Christa E. Müller, Rosaria Volpini, Giulia Costa, Nicola Simola, Annalisa Pinna, Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l-DOPA-induced rotational behavior in a rodent model of Parkinson's disease, Journal of Neurochemistry, 2015, 134, 4
  7. 7
    Sebastian H Scharf, Georg Jaeschke, Joseph G Wettstein, Lothar Lindemann, Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome, Current Opinion in Pharmacology, 2015, 20, 124

    CrossRef

  8. 8
    Matthieu F. Bastide, Wassilios G. Meissner, Barbara Picconi, Stefania Fasano, Pierre-Olivier Fernagut, Michael Feyder, Veronica Francardo, Cristina Alcacer, Yunmin Ding, Riccardo Brambilla, Gilberto Fisone, A. Jon Stoessl, Mathieu Bourdenx, Michel Engeln, Sylvia Navailles, Philippe De Deurwaerdère, Wai Kin D. Ko, Nicola Simola, Micaela Morelli, Laurent Groc, Maria-Cruz Rodriguez, Eugenia V. Gurevich, Maryka Quik, Michele Morari, Manuela Mellone, Fabrizio Gardoni, Elisabetta Tronci, Dominique Guehl, François Tison, Alan R. Crossman, Un Jung Kang, Kathy Steece-Collier, Susan Fox, Manolo Carta, M. Angela Cenci, Erwan Bézard, Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease, Progress in Neurobiology, 2015, 132, 96

    CrossRef

  9. 9
    Cornelis J Van der Schyf, Rational drug discovery design approaches for treating Parkinson’s disease, Expert Opinion on Drug Discovery, 2015, 10, 7, 713

    CrossRef